← Back to Clinical Trials
Recruiting NCT06602648

NCT06602648 MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06602648
Status Recruiting
Phase
Sponsor University of Florence
Condition Melanoma of Skin
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2024-04-17
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age 30 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2024-04-17 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to investigate a type of skin cancer, also known as melanoma, in children, adolescents, and young adults, who will be referred to as CAYA patients in this project. The need for this study arises because this disease, in CAYA patients, is still poorly understood due to its rarity in individuals under 30 years old. This often leads to difficulties in assessing its severity and, consequently, in deciding on the necessary treatments to ensure the patient\'s recovery. The goal of this study is to examine melanoma in CAYA patients in order to gather the information needed to provide better diagnoses for affected patients and, as a result, select appropriate treatments to fight the disease and promote the patient\'s full recovery. Additionally, the data collected will be used to create a Pan-European online platform that will allow doctors across the European Union to consult the obtained data and collaborate on particularly complex melanoma cases, always with the aim of ensuring the patient\'s full recovery in the shortest possible time.

Eligibility Criteria

Inclusion Criteria: * adolescent and childhood patients (\< 20 years) or young adults (\< 30 years) * histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm (i.e., melanocytomas, SAMPUS, IAMPUS and MELTUMP according to WHO classification) Exclusion criteria: * adult patients (\> 30 years of age) * patients without histologically confirmed diagnosis of melanoma or intermediate/ambiguous melanocytic neoplasm

Contact & Investigator

Central Contact

Daniela Massi Professor

✉ daniela.massi@unifi.it

📞 3925536585

Principal Investigator

Massi Daniela

PRINCIPAL INVESTIGATOR

University of Florence (UNIFI)

Frequently Asked Questions

Who can join the NCT06602648 clinical trial?

This trial is open to participants of all sexes, up to 30 Years, studying Melanoma of Skin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06602648 currently recruiting?

Yes, NCT06602648 is actively recruiting participants. Contact the research team at daniela.massi@unifi.it for enrollment information.

Where is the NCT06602648 trial being conducted?

This trial is being conducted at Florence, Italy.

Who is sponsoring the NCT06602648 clinical trial?

NCT06602648 is sponsored by University of Florence. The principal investigator is Massi Daniela at University of Florence (UNIFI). The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology